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Background
Despite all our measures, rates of the allergic diseases in
Kazakhstan is steadily increasing every year. Drug allergy
and in particular allergic reactions to asthma medication is
also a growing problem.
The aim of this study was to assess the frequency of
budesonide/formoterol adverse effects.
Methods
Ninety-three patients with moderate to severe uncon-
trolled asthma from rural outpatient clinics were included
in this study. 54 women and 39 men, their age ranged
from 19 to 61 years (average 35.6±4.53). None of them has
ever used the combination of budesonide and formoterol
before. Every subject underwent a 3-month treatment
with budesonide/formoterol, daily doses of budesonide
ranged from 640 to 960 mcg depending on the severity of
the disease. Tolerability of budesonide/formoterol and its
adverse effects occurrence were evaluated.
Results
Only 5.4% of subject group experienced one or another
adverse effect and only in one case, it was sufficient reason
to stop the treatment. Patient experienced rapid angioe-
dema with upper airway obstruction on the very first day
of treatment. It is necessary to notice, that he has severe
polyvalent drug allergy and cannot tolerate majority of
other anti-asthmatic drugs. Only other adverse effect that
occurred during treatment (in 4.3% of cases) is xerostomia
(mouth dryness). It was easily eliminated by rinsing the
mouth.
Conclusions
The combination of budesonide and formoterol showed
good tolerability with only 5 cases of adverse effects,
majority of which (80%) were easily eliminated and
didn’t become a reason to stop treatment.
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